New pivotal phase III results positioning the nonsteroidal anti-inflammatory Ampion for potential approval in severe osteoarthritis of the knee (OAK) pushed shares of its developer, Ampio Pharmaceuticals Inc. (NYSE:AMPE), to touch a 52-week high on Thursday before pulling back somewhat, closing 33.1 percent higher at $2.33.